500
Participants
Start Date
August 31, 2013
Primary Completion Date
April 30, 2015
Study Completion Date
June 30, 2015
ALV003
ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
placebo
New York
Great Neck
Poughkeepsie
Rochester
Pittsburgh
Philadelphia
Malvern
Chevy Chase
Baltimore
Alexandria
Virginia Beach
Winston-Salem
Salisbury
Asheville
Mt. Pleasant
Atlanta
Jacksonville
Jacksonville
Orlando
Hollywood
Miami
Miami
Boynton Beach
Largo
Naples
Decatur
Huntsville
Huntsville
Hermitage
Chattanooga
Jackson
Mentor
Cleveland
Cincinnati
Dayton
Chesterfield
Wyoming
Des Moines
Milwaukee
Madison
Rochester
Evanston
Oak Lawn
Chicago
Chicago
Kansas City
Mexico
Topeka
Oklahoma City
Tulsa
Irving
Southlake
Houston
Aurora
Idaho Falls
Meridian
West Jordan
Scottsdale
Scottsdale
Tucson
Los Angeles
Los Angeles
Oceanside
Poway
San Marcos
San Diego
Newport Beach
Orange
Palo Alto
San Jose
Modesto
Roseville
Portland
Bellevue
Seattle
Bridgeport
Boston
Marlton
Warwick
Edmonton
Vancouver
Hamilton
Ottawa
Toronto
Tampere
Galway
Oslo
Sheffield
Lead Sponsor
Alvine Pharmaceuticals Inc.
INDUSTRY